News | Proton Therapy | June 28, 2022

Flash therapy delivers radiation at ultra-high dose rates in typically less than one second and is capable of being over 100 times faster compared to conventional radiation therapy 

Flash therapy delivers radiation at ultra-high dose rates in typically less than one second and is capable of being over 100 times faster compared to conventional radiation therapy

June 27, 2022 — Varian, a Siemens Healthineers company, announced that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to advance Varian's Flash clinical research program with the FAST-02 (FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases) clinical trial. Data from FAST-01, the first-ever human clinical trial of Flash, was used to support the approval of the FAST-02 study and will be reported later this year.
The FAST-02 clinical trial builds on the clinical evidence from FAST-01 and will include bone metastases in the chest, providing critical insights into the clinical use of Flash treatment for cancer metastases.
FAST-02 is expected to enroll 10 patients with painful thoracic bone metastases and aims to evaluate treatment-related side effects and efficacy of treatment, which will be assessed using trial participants' reported pain relief.
Similar to FAST-01, FAST-02 was designed with input from leading scientific experts from the FlashForward Consortium and will be conducted at the Cincinnati Children's/UC Health Proton Therapy Center with John C. Breneman, M.D., FASTRO, as principal investigator.
"For the last decade, radiation oncologists have been exploring Flash therapy as an important opportunity to create a paradigm shift in the way we treat patients," said Breneman, Medical Director of the Cincinnati Children's/UC Health Proton Therapy Center, University of Cincinnati Cancer Center member. "The FAST-01 trial laid the groundwork for the approval of FAST-02, and we are excited to continue the clinical research and evaluate Flash therapy in a new patient cohort."
In connection with the FAST-02 clinical trial, the Varian ProBeam® system's proton particle accelerator has been modified to deliver Flash therapy, and Varian's Eclipse™ treatment planning system has also been modified to create plans for the Flash treatments. Varian is the only industry partner to advance the development of Flash therapy as an integrated, end-to-end solution that includes innovations in treatment planning, quality assurance, and therapy delivery technologies.
"Receiving IDE approval for FAST-02 reaffirms our confidence in the potential of Flash therapy and represents an important step toward delivering this groundbreaking therapy in a clinical setting," said Agam Sharda, Vice President of Flash Solutions at Varian. "Together with our FlashForward Consortium, we have expanded Flash therapy research using our systems as we work to improve the patient experience. We look forward to continuing to collaborate with experts around the world to push the boundaries of innovation in cancer care."
"Preclinical research of Flash therapy indicates using ultra-high dose rates may be less toxic to patients overall and enhances sparing of adjacent healthy tissue," said Deepak "Dee" Khuntia, M.D., Senior Vice President and Chief Medical Officer of Varian. "The FAST-02 study will advance our work toward an important proof of concept, particularly in deep-seated tumors. We are eager to build on our clinical understanding of Flash therapy as we continue our work to transform cancer care."

About Flash Therapy

Flash therapy, an experimental treatment modality delivering radiation therapy at ultra-high dose rates in typically less than one second, may be over 100 times faster compared to conventional radiation therapy. The concept of ultra-high dose rate radiation delivery has been studied for many years. Dedicated research and development by the team at Varian has led the advancement of clinical evidence for proton Flash therapy. Varian's efforts include investing in bench and preclinical research and supporting the FlashForward™ Consortium, a group of dozens of institutions from around the world, which includes experts in radiation oncology, translational sciences and medical physics.  

For more information: www.varian.com 

Related ASTRO 2021 Radiation Oncology Content: 

VIDEO: First FLASH Proton Therapy Trial Completed in Humans 

7 Trends in Radiation Therapy at ASTRO 2021 

Radiation Oncology Research Featured at ASTRO 2021  

Photo Gallery of Technologies at ASTRO 2021 

VIDEO: Sedating Children With Movies Rather Than Drugs for Radiation Therapy — Interview with Jeffrey T. Chapman 

VIDEO: 4 Radiation Oncology Technologies to Watch — Interview with Anthony Zietman, M.D. 

VIDEO: Advances in Radiopharmaceutical Therapy — Interview with Ana Kiess, M.D., Ph.D. 

VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare — Interview with Walter Curran, Jr. M.D.,  

VIDEO: Elekta Harmony Radiotherapy System Walk-around 

VIDEO Example of the Varian Noona Bidirection Oncology Patient Interface Software 

VIDEO: Examples of Cherenkov Radiation Imaging During Radiation Therapy 

Find more radiation oncology technology news 


Related Content

News | Radiation Therapy

June 19, 2024 — RaySearch Laboratories AB announced a milestone in radiotherapy technology where RaySearch’s RayStation ...

Time June 19, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | Artificial Intelligence

June 11, 2024 — A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and ...

Time June 11, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
arrow
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
arrow
News | Information Technology

June 4, 2024 — International medical imaging IT and cybersecurity company Sectra has launched a new diagnostic IT module ...

Time June 04, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
arrow
Subscribe Now